Drug Trial Radar · NCT01852292
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Last checked: Nov 20, 2026Latest source record: Jul 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
157
Actual
Start
Oct 1, 2013
Primary completion
Mar 30, 2017
Study completion Mar 30, 2017
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 13, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II Study of efficacy and safety of buparlisib (BKM120) plus paclitaxel versus placebo plus paclitaxel in recurrent or metastatic Head and Neck cancer previously pre-treated with a platinum therapy.The primary endpoint was PFS and the key secondary endpoint was Overall Survival.
Conditions
- Head and Neck Squamous Cell Carcinoma
Interventions
BuparlisibDrug
Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
Buparlisib matching PlaceboDrug
Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
PaclitaxelDrug
Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) Per Investigator AssessmentTime frame: 4 weeks and thereafter every 6 weeks until disease progression or death up to 3.5 years
Locations
58 sites in 18 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Fayetteville, Arkansas
Dana Farber Cancer Institute IRB
Boston, Massachusetts
Washington U School of Medicine Center for Clinical Studies SC - BKM120H2201
St Louis, Missouri
The Mount Sinai Hospital Dept of Oncology
New York, New York
University of N.C. at Chapel Hill Lineberger Comp. Cancer Ctr.
Chapel Hill, North Carolina
University Hospitals Case Medical Center Univ. Hospitals of Cleveland
Cleveland, Ohio
UPMC Cancer Centers BKM120H2201
Pittsburgh, Pennsylvania
Novartis Investigative Site
St Leonards, New South Wales, Australia
Novartis Investigative Site
Hamilton, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Saint-Herblain, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Nyíregyháza, Hungary
Novartis Investigative Site
Kerala, India
Novartis Investigative Site
Mumbai, India
Novartis Investigative Site
Nashik, Maharashtra, India
Novartis Investigative Site
Dehli, New Delhi, India
Novartis Investigative Site
Jaipur, Rajasthan, India
Novartis Investigative Site
Kolkata, West Bengal, India
Novartis Investigative Site
Dublin, Ireland
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Palermo, PA, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Salerno, SA, Italy
Novartis Investigative Site
Torino, TO, Italy
Novartis Investigative Site
Venezia, VE, Italy
Novartis Investigative Site
Kashiwa, Chiba, Japan
Novartis Investigative Site
Koto-ku, Tokyo, Japan
Novartis Investigative Site
Minato-ku, Tokyo, Japan
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Nizhny Novgorod, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.